arrow_back Back to App

Ensuring Access to 340B Discount Drugs and Protecting Contract Pharmacies.

This law aims to stop drug manufacturers from restricting hospitals and clinics' access to the 340B drug discount program, particularly concerning the use of contract pharmacies. This ensures healthcare providers can continue purchasing drugs at lower prices, using the savings to expand services for patients, especially those needing specialized treatments. The bill also introduces significant daily fines for manufacturers who intentionally obstruct access to these discounts.
Key points
Drug manufacturers must offer 340B discounts regardless of where or how the drug is dispensed, including through contract pharmacies.
Manufacturers are prohibited from imposing conditions that limit healthcare facilities' ability to purchase and distribute discounted drugs.
New civil monetary penalties of up to $2 million per day are established for manufacturers who knowingly violate 340B access rules.
The law secures patient access to vital, often expensive, specialty drugs frequently distributed only via contract pharmacy arrangements.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_7635
Sponsor: Rep. Matsui, Doris O. [D-CA-7]
Process start date: 2024-03-12
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

The 340B PATIENTS Act of 2024

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_7635.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-03-12.

What are the main provisions?

Key points include:

  • Drug manufacturers must offer 340B discounts regardless of where or how the drug is dispensed, including through contract pharmacies.
  • Manufacturers are prohibited from imposing conditions that limit healthcare facilities' ability to purchase and distribute discounted drugs.
  • New civil monetary penalties of up to $2 million per day are established for manufacturers who knowingly violate 340B access rules.
  • The law secures patient access to vital, often expensive, specialty drugs frequently distributed only via contract pharmacy arrangements.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Matsui, Doris O. [D-CA-7].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-30.

CATEGORIES

Health